Kristin Price, MS, CGC (@k_sedge) header
Kristin Price, MS, CGC (@k_sedge) profile picture

Product leader @guardanthealth. Specializing in ctDNA & developing tools to support more personalized oncology care.

Boston, MA
Joined June 2010
Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)Photo by Kristin Price, MS, CGC (@k_sedge)
Less patients getting unnecessary chemotherapy is a HUGE win. So exciting to see this clinical utility data from ctDNA MRD testing.
DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 nej.md/3x0jR94
1
Kristin Price, MS, CGC retweeted
Very proud of our new paper: Common germline-somatic variant interactions in advanced urothelial cancer nature.com/articles/s41467-0… Tweetorial to follow.
22
63
14
298
A great story of hope. We have so far to go to improve cancer treatment, but there have been amazing improvements giving patients more time with they people they love (and more quality time on less toxic drugs). This is what motivates me. nytimes.com/2021/09/27/healt…
Congrats to @aparna1024 @TedHong9 @KlempnerSam & MGH team on the CCR pub showing Guardant Reveal plasma-only MRD assay for #CRC has comp sensitivity & specificity to tumor-informed assays. No tissue need & fast TAT has great potential to help more pts. clincancerres.aacrjournals.o…
1
2
15
Key to strong performance w/out tissue is the multiomic nature of the assay. Adding methylation to genomic analysis increased sensitivity by 36% in the setting of a single post-tx draw- it is sort of like adding more needles to the haystack when looking for signs of MRD!
1
4
Kristin Price, MS, CGC retweeted
We’re excited to launch Guardant Reveal, the first blood-only #liquidbiopsy test for residual disease and recurrence monitoring of early-stage #colorectalcancer patients. #MRD https://nitter.cf/t.co/3GsP9X1vgu
1
14
4
28
Kristin Price, MS, CGC retweeted
Pralsetinib (BLU-667), #RET inhibitor is now FDA approved, further expanding treatment options for our patients. Congratulations to @JustinGainor and co-investigators, and thanks to all patients and families for their contributions! onclive.com/view/fda-approve… #NSCLC #LCSM
5
21
Kristin Price, MS, CGC retweeted
non-smoker in 40s with egfr/alk/ros -/ pd-l1 high+ lung adeno from OSH after chemo/io failure w leptomeningeal disease, pall care discussed ?Can we just send 2 tubes of blood? Results:👇 We should rename NGS➡️ NMP (no malpractice) - might make it easier to remember to order it...
2
9
4
48
Important to remember to #Test for #Actionable Mutations using #NGS in patients with metastatic #NSCLC prior to using immunotherapy. #Plasma is a meaningful way to test. There are important efficacy and toxicity implications. Nicely summarized by @Tony_Calles et al #ASCO20
📚 Glad to share our book chapter in the 2020 @ASCO Educational Book: 'Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely'. 👉 Free access! #LCSM #OncoAlert #ASCO20 #EdBook #ImmunOnc ascopubs.org/doi/abs/10.1200…
5
2
19
Excited to see the approval of #capmatinib for #METex14 skipping NSCLC. Data from GEOMETRY shows higher ORR in first-line setting (68% 1L and 41% 2/3L) - highlights importance of early molecular testing. Thanks @BeccaHeistMD and @MGHThoracicOnc for helping to make this happen!!
1
3
Also important to remember that @JSabari & team showed that pts with MET exon 14 skipping mutations have poor response to ICB. ORR was 17% and the median PFS was 1.9 months. Responses were not enriched in tumors with PD-L1 expression ≥50% nor high TMB.
1
Definitely time to add #MetExon14 to testing at diagnosis for all lung cancer patients? I say yes!
Garon: capmatinib in GEOMETRY study #MetExon14 pts. Impressive ORR 41% in 69 pre-treated pts and 68% in 28 rx-naive pts. Early data on CNS responses promising. AE's very tolerable, mostly LE swelling, nausea. This is exciting data! #AACR2020 #LCSM #OncoAlert
4
14
53
Encorafenib/Cetuximab Combo now FDA approved for #BRAF pos #mCRC. Data we published last year with @cotahealthcare showed that testing rates for BRAF in 2017 were around 50%. Let's make sure more patients get access to comprehensive testing in 2020. onclive.com/web-exclusives/f…
1
3
Kristin Price, MS, CGC retweeted
Here’s a useful overview of the likely scenarios that the world will be facing in the coming months while managing this pandemic. So much depends on our ability to make good decisions going forward along with our ability to remain resilient. theatlantic.com/health/archi…
6,930
45,066
5,105
159,291
Kristin Price, MS, CGC retweeted
ICYMI: #Osimertinib plus #savolitinib in patients with #EGFR mutation-positive, MET-amplified, #nonsmallcelllungcancer after progression on EGFR tyrosine kinase inhibitors: interim results from the phase 1b TATTON study thelancet.com/journals/lanon…
1
12
17
Kristin Price, MS, CGC retweeted
So sad that #patients who are not tested risk getting less than the best treatment for their #colorectalcancer. #GI20 @FightCRC
Molecular testing including MSI status, KRAS, NRAS, BRAF should be tested for all mCRC cases. Currently tested in about 50% of cases. @ASCO @COLONTOWN #gi20 #colorectalcancer #CRCSM
1
5
16